RD140 achieved ~89% ORR & MRD negativity rate in heavily pretreated, high-risk RRMM or plasma cell leukemia patients 

“We are very pleased to present preliminary data from the first-in-human study of RD140 at this year’s IMS Annual Meeting. In patients with relapsed/refractory multiple myeloma (R/R MM) and plasma cell leukemia (PCL) — all triple-class exposed, mostly penta-exposed, and high-risk — RD140, leveraging its BCMA/GPRC5D dual-target design, achieved an objective response rate (ORR) of 88.9% and an exceptionally high MRD negativity rate, with no immune effector cell-associated neurotoxicity syndrome (ICANS) of any grade observed. Of particular note, the FasT CAR-T rapid manufacturing platform enables cell manufacturing to be completed in just 3–4 days, significantly shortening the waiting time for patients and securing a valuable treatment window for more critically ill patients.”

Share:

More News

Taiho Oncology, Inc. completed a New Drug Application (NDA) submission to the U.S. Food and Drug Administration (FDA) for zipalertinib in combination with platinum-based chemotherapy for the treatment of patients with previously untreated, locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) exon 20

“This collaboration reflects our conviction that atebimetinib has the potential to become an essential backbone therapy in a broad range of combinations across MAPK-driven cancers,” said Ben Zeskind, Immuneering CEO and co-founder. “Atebimetinib’s unique tolerability profile and broad activity make it well suited to combine with a wide range of

“These final updated results provide continued evidence of the potential for γδ T cell therapies to drive activity and improve outcomes for patients,” said William Ho, CEO and co-founder of IN8bio. “The clinical outcomes and observed activity are supported by our correlative analysis, including histopathology, demonstrating the expansion and persistence

“Patients with RAS-mutated mCRC have no first-line therapies specifically approved for their disease, and Fast Track designation reflects the potential of onvansertib to address this serious unmet need,” said Mani Mohindru, PhD, President and Chief Executive Officer of Cardiff Oncology. “Our randomized Phase 2 data give us confidence that onvansertib